8-K: Silence Therapeutics Reports Q2 2025 Results

Silence Therapeutics reported its second quarter 2025 financial results, highlighting progress in its clinical trials and reiterating its cash runway guidance into 2028.

Summary

• Net loss for the second quarter ended June 30, 2025, was $27.4 million, compared to $19.8 million for the same period in 2024.
• Cash and cash equivalents and short-term investments totaled $114.2 million as of June 30, 2025.
• The company reiterated its cash runway guidance, expecting current funds to support operational plans into 2028.
• Research & Development expenses increased to $17.6 million in Q2 2025 from $13.8 million in Q2 2024, primarily due to advancement of clinical trials and increased contract manufacturing activities.
• General & Administrative expenses decreased to $5.1 million in Q2 2025 from $7.0 million in Q2 2024, driven by reduced reporting and compliance requirements and efforts to increase operating efficiencies.
• The SANRECO Phase 2 trial for divesiran in Polycythemia Vera (PV) has exceeded 50% enrollment and remains on track for complete enrollment by year-end 2025.
• Updated SANRECO Phase 1 data for divesiran presented at EHA 2025 showed durable hematocrit control (<45%), eliminated the need for phlebotomies, increased hepcidin and ferritin, and was well tolerated.
• Core Phase 3 readiness activities, including manufacturing and supply scale-up, have been completed for zerlasiran for Cardiovascular Disease, with ongoing dialogues for potential third-party partners.
• The company is prioritizing extra-hepatic cell targeting of siRNA due to promising initial preclinical activity in mice models, leading to a decision to pause initiating a Phase 1 study of SLN548 for complement-mediated diseases.
• A Phase 1 study of SLN312, licensed to AstraZeneca, is ongoing.

Sentiment

Score: 6

Explanation: While financial losses increased and revenue declined, the company maintains a strong cash position with a runway into 2028, and its key clinical program (SANRECO Phase 2) is on track with encouraging Phase 1 data. Strategic re-prioritization of R&D efforts is also noted, indicating a focused approach.

Positives

• Maintained a strong cash position of $114.2 million as of June 30, 2025.
• Reiterated cash runway guidance into 2028, indicating financial stability for the medium term.
• SANRECO Phase 2 trial for divesiran in Polycythemia Vera (PV) is on track for complete enrollment by year-end 2025, having exceeded 50% enrollment.
• Updated SANRECO Phase 1 data for divesiran showed compelling therapeutic profile, including durable hematocrit control (<45%), elimination of phlebotomy need, improved iron deficiency, and good tolerability with no dose-limiting toxicities.
• Completed core Phase 3 readiness activities for zerlasiran, including manufacturing and supply scale-up.
• General & Administrative expenses decreased to $5.1 million in Q2 2025 from $7.0 million in Q2 2024 due to reduced reporting/compliance and increased operating efficiencies.
• Promising initial preclinical activity observed in extra-hepatic cell targeting of siRNA in mice models.

Negatives

• Net loss increased to $27.4 million for Q2 2025 from $19.8 million for Q2 2024.
• Research & Development expenses increased to $17.6 million for Q2 2025 from $13.8 million for Q2 2024, driven by clinical trial advancement and contract manufacturing.
• Revenue significantly decreased to $0.224 million for Q2 2025 from $0.756 million for Q2 2024, and to $0.366 million for the six months ended June 30, 2025, from $16.455 million for the same period in 2024.
• Operating loss increased to $23.963 million for Q2 2025 from $23.388 million for Q2 2024.
• Foreign currency loss increased significantly to $6.613 million for Q2 2025 from $0.222 million for Q2 2024.
• Decision to pause initiating a Phase 1 study of SLN548 (wholly owned siRNA for complement-mediated diseases) to prioritize extra-hepatic activities.

Risks

• History of net operating losses.
• Ability to obtain necessary capital to fund clinical programs.
• Early stages of clinical development of product candidates.
• Ability to obtain regulatory approval of and successfully commercialize product candidates.
• Undesirable side effects or other properties of product candidates.
• Reliance on third-party suppliers and manufacturers.
• Outcomes of any future collaboration agreements.
• Ability to adequately maintain intellectual property rights for product candidates.

Future Outlook

The company anticipates completing enrollment for the SANRECO Phase 2 trial by year-end 2025 and expects its current cash and investments to fund operations into 2028. It is also actively seeking third-party partners for Phase 3 development and potential commercialization of zerlasiran. The company is prioritizing extra-hepatic cell targeting of siRNA based on promising preclinical activity.

Management Comments

• "The updated data we presented at EHA this past quarter were highly encouraging and supportive of the therapeutic potential of divesiran as a first-in-class siRNA in PV." Craig Tooman, President and Chief Executive Officer.
• "The SANRECO Phase 2 trial of divesiran in PV patients continues to progress towards full enrollment this year and remains our top priority." Craig Tooman, President and Chief Executive Officer.
• "We are continuing to prioritize investments in key areas where we see the highest potential to deliver near term value, including ensuring the successful completion of the SANRECO Phase 2 trial enrollment by year-end." Rhonda Hellums, Chief Financial Officer.
• "We ended the quarter with approximately $114.2 million in cash and cash equivalents and short-term investments and are reiterating our cash runway guidance into 2028." Rhonda Hellums, Chief Financial Officer.

Industry Context

Silence Therapeutics operates in the competitive and rapidly evolving siRNA therapeutics space, focusing on precision-engineered medicines. The company's progress in clinical trials for Polycythemia Vera and Cardiovascular Disease, alongside its strategic decision to pause a Phase 1 study to prioritize extra-hepatic targeting, reflects the dynamic nature of drug development where companies must balance pipeline advancement with resource allocation and emerging scientific opportunities. The pursuit of third-party partnerships for late-stage development is a common strategy in biotech to de-risk and fund expensive Phase 3 trials and commercialization.

Comparison to Industry Standards

• The company's cash runway into 2028 is a strong position compared to many clinical-stage biotechnology companies, which often face more immediate capital needs.
• The progress of the SANRECO Phase 2 trial, exceeding 50% enrollment and on track for year-end completion, indicates efficient trial execution, which is critical in a competitive therapeutic area like PV.
• The decision to pause SLN548 to prioritize extra-hepatic siRNA targeting aligns with industry trends of focusing resources on areas with the highest scientific promise and market potential, even if it means re-prioritizing existing pipeline assets.
• Seeking third-party partners for zerlasiran's Phase 3 development is a standard industry practice for smaller biotech firms to share the substantial costs and risks associated with late-stage clinical trials and commercialization, similar to partnerships seen with companies like Alnylam Pharmaceuticals or Ionis Pharmaceuticals in the RNA therapeutics space.

Stakeholder Impact

• Shareholders: Potential for long-term value creation if clinical programs succeed, but current increased losses and reduced revenue may impact short-term sentiment. Reiteration of cash runway provides stability.
• Employees: Continued investment in R&D and clinical trials suggests ongoing work, but re-prioritization of SLN548 could imply shifts in internal project focus.
• Customers (future patients): Progress in divesiran and zerlasiran clinical trials offers hope for new therapeutic options in PV and cardiovascular disease.
• Partners (AstraZeneca): Ongoing Phase 1 study for SLN312 indicates continued collaboration.

Next Steps

• Complete enrollment for the SANRECO Phase 2 trial by year-end 2025.
• Continue dialogues with potential third-party partners for Phase 3 development and future commercialization of zerlasiran.
• Advance extra-hepatic cell targeting of siRNA.

Key Dates

Recommendation

While the financial results show increased losses and a significant drop in revenue, the company's strong cash position with a runway into 2028 provides stability. The clinical progress, particularly with divesiran's SANRECO Phase 2 trial being on track and positive Phase 1 data, is a key driver for future value. The strategic decision to pause SLN548 to focus on promising extra-hepatic siRNA targeting is a rational allocation of resources. Given the mixed financial performance but solid clinical and cash outlook, a 'hold' recommendation is appropriate, awaiting further clinical milestones and partnership developments.

Keywords

siRNA, RNA therapeutics, Polycythemia Vera, Cardiovascular Disease, Divesiran, Zerlasiran, SANRECO, clinical trials, biotechnology, drug development, hematology, rare diseases, financial results